BylvayTM (odevixibat) Approved

Bylvay is now approved in the U.S. and EU

 

DISCOVER MORE   

Targeted Expertise.
Brighter Outcomes.
New Treatment.

Learn about Progressive Familial Intrahepatic Cholestasis (PFIC) and a new drug treatment available.

LEARN MORE

Backed by Deep Knowledge of IBAT Inhibition

Dedicated to the development of novel bile acid modulators to relieve the pain and suffering of people living with orphan liver diseases.

Read Our Science

Better Pediatric Liver Solutions are in Development

Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology.

View Pipeline

Albireo's Bylvay is a potent and selective IBAT inhibitor

View Bylvay's MOA

 

A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators

We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder.

Download Now

Recent News, Events & Presentations